Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Part A Clear all
Completed Not applicable Interventional Results available

High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

NCT04550676
View directory record Official record
Conditions
Hiv, Fatigue, Mobility Limitation
Interventions
HIIT (intervention), CME (active control), Coaching, Control text message
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 3, 2026, 1:08 PM EDT
Terminated Phase 3 Interventional

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

NCT02326740
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
gevokizumab, Placebo, gevokizumab open-label
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Oceanside, California • Tampa, Florida • Macon, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Sep 3, 2026, 1:08 PM EDT
Not listed Phase 1 Interventional

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

NCT04021368
View directory record Official record
Conditions
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Interventions
RVU120(SEL120)
Drug
Lead sponsor
Ryvu Therapeutics SA
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 3, 2026, 1:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Massage: Neuroimaging and Correlates of Response - 6-week Study

NCT07190326
View directory record Official record
Conditions
Healthy Control
Interventions
Swedish Massage Therapy, Light Touch Control
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 1:08 PM EDT
Terminated No phase listed Observational

Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

NCT05605678
View directory record Official record
Conditions
Hemophilia a, Hemophilia B
Interventions
No Intervention
Other
Lead sponsor
ApcinteX Ltd
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 3, 2026, 1:08 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

NCT05231785
View directory record Official record
Conditions
Early-Onset Alzheimer Disease
Interventions
ALN-APP, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
La Jolla, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

NCT01821833
View directory record Official record
Conditions
Breast Cancer, Ovarian Neoplasm, Pain
Interventions
Omega-3 fatty acid, Placebo, Paclitaxel
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

NCT00423852
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, ifosfamide, paclitaxel, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

NCT06054815
View directory record Official record
Conditions
NON-ALCOHOLIC STEATOHEPATITIS
Interventions
DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Coronado, California • Montclair, California • Panorama City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 3, 2026, 1:08 PM EDT
Recruiting Phase 1 Interventional

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

NCT06582017
View directory record Official record
Conditions
Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Interventions
QXL138AM Injection every 2 weeks by IV Infusion
Biological
Lead sponsor
Nammi Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Newport, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers

NCT06543043
View directory record Official record
Conditions
Not Determined
Interventions
Phenytoin, Itraconazole, sonrotoclax
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

NCT00544817
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Radiation Therapy, Temozolomide, Sorafenib
Radiation · Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Fort Myers, Florida • Gainesville, Georgia • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Sep 3, 2026, 1:08 PM EDT
Completed No phase listed Observational

Strep A FIA Field Study, Sofia

NCT02153008
View directory record Official record
Conditions
Group A Streptococcus
Interventions
Not listed
Lead sponsor
Quidel Corporation
Industry
Eligibility
3 Years and older
Enrollment
1,708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Phoenix, Arizona • Boynton Beach, Florida • Delray Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Sep 3, 2026, 1:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advancing the Role of the Neonatal Registered Dietitian Nutritionist

NCT06771778
View directory record Official record
Conditions
Opinions of the Neonatal Registered Dietitian
Interventions
Survey using a questionnaire.
Other
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Not applicable Interventional Results available

InnFocus MicroShunt Versus Trabeculectomy Study

NCT01881425
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Glaucoma Surgery, InnFocus MicroShunt
Procedure · Device
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Effectiveness of the Community Reinforcement Approach and Family Training (CRAFT) With American Indians

NCT03203889
View directory record Official record
Conditions
Substance Use Disorders, Family Members
Interventions
CRAFT-AI, TSF-CSO
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Zuni, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Ghrelin (OXE--103) for Acute Concussion Management

NCT04558346
View directory record Official record
Conditions
Concussion, Brain, Traumatic Brain Injury
Interventions
Ghrelin (OXE-103), Placebo
Drug
Lead sponsor
Michael Rippee
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 3, 2026, 1:08 PM EDT
Not listed No phase listed Observational

Radiostereometric Analysis of Spine Arthrodesis

NCT01721889
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
Radiostereometric Analysis
Radiation
Lead sponsor
OAD Orthopaedics
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Sep 3, 2026, 1:08 PM EDT
Recruiting No phase listed Observational

Weight Loss in Adults Using Semaglutide (Real-world Study)

NCT07627074
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
35,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

NCT03595059
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ABBV-155, Paclitaxel, Docetaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
21
States / cities
Birmingham, Alabama • Springdale, Arkansas • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 3, 2026, 1:08 PM EDT
Terminated Phase 4 Interventional Results available

PIEB vs CEI for Labor Analgesia: An MLAC Study

NCT02573597
View directory record Official record
Conditions
Pregnancy
Interventions
Bupivacaine, Sufentanil
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 3, 2026, 1:08 PM EDT
Not yet recruiting Not applicable Interventional

Supporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative

NCT07720388
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes
Interventions
Culturally and linguistically tailored onboarding and support program, Medtronic MiniMed 780G Insulin Pump System
Other · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 20 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 3, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

DAY101 In Gliomas and Other Tumors

NCT03429803
View directory record Official record
Conditions
Low-grade Glioma
Interventions
DAY101
Drug
Lead sponsor
Karen D. Wright, MD
Other
Eligibility
1 Year to 25 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 3, 2026, 1:08 PM EDT